ArticleChest2008
COPD in Asia: where East meets West.
Article in Chest, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02898129 (Evaluating the Relationship Between Environmental Risk Factors in Housing Types and Chronic Respiratory Diseases in Ho Chi Minh City), which is not on this map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluating the Relationship Between Environmental Risk Factors in Housing Types and Chronic Respiratory Diseases in Ho Chi Minh City
Who cites it
38 citing papers in PubMed, 93 citations in OpenAlex.
- Efficacy and Safety of Once-Daily Inhaled Umeclidinium in Asian Patients with COPD: Results from a Randomized, Placebo-Controlled Study.International journal of chronic obstructive pulmonary disease · 2020Trial
- Pharmacokinetics of Roflumilast and Its Active Metabolite Roflumilast N-Oxide in Healthy Chinese Subjects After Single and Multiple Oral Doses.European journal of drug metabolism and pharmacokinetics · 2017Trial
- Indacaterol/glycopyrronium versus salmeterol/fluticasone in Asian patients with COPD at a high risk of exacerbations: results from the FLAME study.International journal of chronic obstructive pulmonary disease · 2017Trial
- Efficacy and safety of once-daily inhaled umeclidinium/vilanterol in Asian patients with COPD: results from a randomized, placebo-controlled study.International journal of chronic obstructive pulmonary disease · 2015Trial
- Prevalence of Chronic Obstructive Pulmonary Disease (COPD) in Sri Lankan adults: results of a cross sectional study.BMC pulmonary medicine · 2026Article
- Projecting the 20-year healthcare resource burden of asthma and COPD multimorbidity: insights from Singapore for integrated chronic respiratory care in South-East Asia.NPJ primary care respiratory medicine · 2026Article
- Direct Integration of Ionic Liquid Gel Sensors onto Microfibrous Face Mask Substrates for Wearable Respiratory Health Monitoring.ACS applied bio materials · 2026Article
- Global, Regional, and National Burden of Chronic Obstructive Pulmonary Disease-Associated Heart Failure: A Systematic Analysis of the Global Burden of Disease Study from 1990 to 2021 with Projections up to 2050.International journal of chronic obstructive pulmonary disease · 2026Article
- Healthcare Costs and Trends of Multimorbidity in COPD Patients: A Population-Based Study in Singapore.International journal of chronic obstructive pulmonary disease · 2026Article
- Integrated multi-omics profiling for risk stratification in Asians with COPD.Respiratory research · 2025Article
- Management of COPD With Cardiovascular Risk in Asia: A Review by the Asian Pacific Society of Respirology COPD Assembly.Respirology (Carlton, Vic.) · 2025Review
- The burden and risk factors of chronic obstructive pulmonary disease in Asia and its countries from 1990 to 2021: a systematic analysis based on the 2021 global burden of disease study.Frontiers in medicine · 2025Article
- The association between anti-smoking legislation and prevalence of acute respiratory illnesses in Indian children.Public health in practice (Oxford, England) · 2024Article
- Risk of Death and Cardiovascular Events in Asian Patients With Atrial Fibrillation and Chronic Obstructive Pulmonary Disease: A Report From the Prospective APHRS Registry.Journal of the American Heart Association · 2024Observational
- Sociodemographic correlates with prevalence of comorbidities in patients with chronic obstructive pulmonary disease: a study from a Chinese National Survey.The Lancet regional health. Western Pacific · 2024Article
- Article
- Development and validation of a prediction index for recent mortality in advanced COPD patients.NPJ primary care respiratory medicine · 2022Article
- Triple Versus Dual Combination Therapy in Chronic Obstructive Pulmonary Disease in Asian Countries: Analysis of the IMPACT Trial.Pulmonary therapy · 2021Article
- Chronic respiratory disease mortality and its associated factors in selected Asian countries: evidence from panel error correction model.BMC public health · 2021Article
- Whole-Exome Sequencing Implicates theFrontiers in cell and developmental biology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
COPD is a global health concern, and is a major cause of chronic morbidity and mortality worldwide. According to the World Health Organization, it is currently the sixth leading cause of death in the world, and further increases in the prevalence and mortality of the disease is predicted for the coming decades. These increases are mainly linked to the epidemic of tobacco exposure and indoor and outdoor air pollution in Asian countries. The burden of COPD in Asia is currently greater than that in developed Western countries, both in terms of the total number of deaths and the burden of disease, as measured in years of life lost and years spent living with disability. The types of health-care policies and the practice of medicine vary considerably among the regions of Asia and have an impact on the burden of disease. Treatment aims in Asian countries are based on evidence-based management guidelines. Barriers to the implementation of disease management guidelines are related to issues of resource conflict and lack of organizational support rather than cultural differences in medical practice. To reduce this burden of COPD in Asian countries, there is a need for a multifaceted approach in improving awareness of prevalence and disease burden, in facilitating accurate diagnosis of COPD among chronic respiratory diseases, in championing health policies that reduce the burden of the main risk factors for COPD and in the wider use of evidence-based management for COPD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.